Why the study?
Does prasugrel monotherapy provide a safe and feasible alternative to traditional DAPT in low-risk Japanese patients with CCS undergoing PCI?
Does prasugrel monotherapy provide a safe and feasible alternative to traditional DAPT in low-risk Japanese patients with CCS undergoing PCI?
Prasugrel monotherapy may be a safe 'aspirin-free' alternative to traditional DAPT following PCI in low-risk patients with chronic coronary syndrome.
Answers are grounded in this paper and cite their sources.
May support prasugrel monotherapy in selected low-risk Japanese CCS; hypothesis-generating and requires randomized confirmation before broader use.
This pilot study showed the safety and feasibility of prasugrel monotherapy in selected low-risk Japanese patients with CCS. This "aspirin-free" strategy may be a safe alternative to traditional DAPT following PCI.
No takes yet. Share an insight, caveat, or question.
Muramatsu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: